title: Comparative efficiency of commercial and improvised spacer device in acute bronchial asthma.
abstract: OBJECTIVE
  To compare the efficacy of a commercial spacer device versus an improvised spacer device in delivering aerosolized beta-2 agonist through metered dose inhaler in an acute exacerbation of bronchial asthma.
  
  
  METHODS
  Randomized controlled trial.
  
  
  METHODS
  Urban tertiary care teaching hospital.
  
  
  METHODS
  60 children between 1 to 12 years of age with acute asthma were prospectively enrolled and randomized into two groups. Detailed history, clinical evaluation and appropriate laboratory investigations were recorded on a pretested proforma. One group received inhaled salbutamol using metered dose inhaler via commercial spacer device (Group 1), while the other received it via improvised spacer device (Group II). The response was sequentially assessed after 20, 40 and 60 minutes of institution of therapy.
  
  
  RESULTS
  The two groups were comparable with respect to various parameters at presentation (p > 0.05). All the outcome parameters showed a significant improvement with time in both groups (p < 0.05). There was no statistical difference between the response in the two groups (p< 0.05).
  
  
  CONCLUSIONS
  Metered dose inhaler with improvised spacer device is equivalent in efficacy and a more cost effective alternative to metered dose inhaler with commercial spacer for administration of beta-2 agonist in acute asthma.
authors: Department of Pediatrics, Maulana Azad Medical College, New Delhi 110 002, India.
authors: J
authors: J
authors: Panicker
authors: G R
authors: GR
authors: Sethi
authors: V
authors: V
authors: Sehgal
mesh_terms: D000280:Administration, Inhalation; D000420:Albuterol / Q000008:administration & dosage*; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D016503:Drug Delivery Systems / Q000295:instrumentation*; D004867:Equipment Design; D004869:Equipment Safety; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009330:Nebulizers and Vaporizers; D011446:Prospective Studies; D012016:Reference Values; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D013224:Status Asthmaticus / Q000175:diagnosis / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D000420:Albuterol